安科生物(300009.SZ):人生長激素注射液獲批新增兩個適應症
格隆匯12月30日丨安科生物(300009.SZ)公佈,近日,公司收到國家藥監局下發的《藥品補充申請批准通知書》,公司人生長激素注射液用於性腺發育不全(特納綜合徵)所致女孩的生長障礙、特發性身材矮小適應症的補充申請已獲批准。
至此,公司的人生長激素注射液已獲批上市8個適應症:1)用於因內源性生長激素缺乏所引起的兒童生長緩慢;2)用於因Noonan綜合徵所引起的兒童身材矮小;3)用於因SHOX基因缺陷所引起的兒童身材矮小或生長障礙;4)用於重度燒傷治療;5)用於因軟骨發育不全所引起的兒童身材矮小;6)用於接受營養支持的成人短腸綜合徵;7)用於性腺發育不全(特納綜合徵)所致女孩的生長障礙;8)用於特發性身材矮小。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.